JPRN-jRCT2080222292未知2 期
A Phase 2 Study of Ramucirumab in the Treatment of Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Following Disease Progression on First Line Platinum- or Fluoropyrimidine-Containing Combination Therapy in Japanese Patients
适应症
试验速览
- 阶段
- 2 期
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Histologically or cytologically confirmed gastric carcinoma, including gastric adenocarcinoma or Gastroesophageal Junction (GEJ) adenocarcinoma
- •- Metastatic disease or locally recurrent, unresectable disease
- •- Measurable disease and/or evaluable disease
- •- Experienced disease progression during or within 4 months after the last dose of first-line therapy for metastatic disease, or during or within 6 months after the last dose of adjuvant therapy
- •- Resolution to Grade less than or equal to 1 by the National Cancer Institute Common Terminology Criteria for Adverse , Version 4.03, of all clinically significant toxic effects of prior chemotherapy, surgery, radiotherapy, or hormonal therapy
- •- Eastern Cooperative Oncology Group performance status score of 0-1
- •- Has adequate organ function
- •- Must be postmenopausal, surgically sterile, or using effective contraception (hormonal or barrier methods), if sexually active
- •- Female participants of childbearing potential must have a negative serum or urine pregnancy test within 7 days prior to enrollment
排除标准
- 未提供
研究者
相似试验
招募中
2 期
Phase II study of ramucirumab for the patients with advanced hepatocellular carcinoma previously treated with lenvatinibHepatocellular carcinomaJPRN-jRCT1041190083Yamashita Tatsuya33
进行中（未招募）
2 期
Phase II study of ramucirumab in combination with erlotinib for untreated EGFR mutation-positive non-squamous non-small cell lung cancer patients with pleural effusion: RELAY-EffusioEGFR mutation positive advanced non-small cell lung cancerJPRN-jRCTs051210138Kaneda Hiroyasu40
未知
1 期
Phase 1b Study of Ramucirumab in Combination With Fluoropyrimidines and Platinum-Based Agents in Japanese Patients With Metastatic Gastric/Gastroesophageal Junction AdenocarcinomaStomach NeoplasmsJPRN-jRCT2080222764Eli Lilly Japan K.K.
进行中（未招募）
1 期
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyStage IV non-small cell lung cancer (NSCLC)MedDRA version: 19.0Level: LLTClassification code 10025048Term: Lung cancer non-small cell recurrentSystem Organ Class: 100000004864EUCTR2016-001317-25-ESilly S.A.50
进行中（未招募）
1 期
A Phase 2 Study of Ramucirumab in Combination with Weekly Docetaxel in Patients with Lung Cancer Following Disease Progression after Prior Platinum-based ChemotherapyEUCTR2016-001317-25-ITELI LILLY & COMPANY, LILLY CORPORATE CENTER50